Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application To U.S. FDA

Velcura Therapeutics Inc., an early stage biotechnology company developing therapies for bone disease, recently completed a successful Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA). The IND enables Velcura to proceed with the first-in-man clinical trials for its lead compound, VEL-0230.

More: continued here

Filed under: Bones on January 29th, 2008